[1] MANNING G, WHYTE D B, MARTINEZ R, et al. The protein kinase complement of the human genome[J].Science, 2002, 298(5600):1912-1934. [2] WAGNER E F, NEBREDA ÁR. Signal integration by JNK and p38 MAPK pathways in cancer development[J].Nat Rev Cancer, 2009, 9(8):537-549. [3] SEKI E, BRENNER D A, KARIN M. A liver full of JNK:signaling in regulation of cell function and disease pathogenesis, and clinical approaches[J].Gastroenterology, 2012, 143(2):307-320. [4] RODRIGUES G A. Activation of the JNK pathway is essential for transformation by the Met oncogene[J]. EMBO J, 1997, 16(10):2634-2645. [5] BEHRENS A, JOCHUM W, SIBILIA M, et al. Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphorylation[J].Oncogene, 2000, 19(22):2657-2663. [6] BUBICI C, PAPA S.JNK signalling in cancer:in need of new, smarter therapeutic targets.[J]. Br J Pharmacol, 2014,171(1):24-37. [7] WANG J, LIU G M, LI Q S, et al. Mucin1 promotes the migration and invasion of hepatocellular carcinoma cells via JNK-mediated phosphorylation of Smad2 at the C-terminal and linker regions[J].Oncotarget,2015, 6(22):19264-19278. [8] LI Q S, LIU G M, YUAN H Y, et al. Mucin1 shifts Smad3 signaling from the tumor-suppressive pSmad3C/p21(WAF1) pathway to the oncogenic pSmad3L/c-Myc pathway by activating JNK in human hepatocellular carcinoma cells[J].Oncotarget, 2015, 6(6):4253-4265. [9] FIRE AZ.Gene silencing by double stranded RNA[J].Cell Death Differ, 2007,14(12):1998-2012. [10] PECOT C V, WU S Y, BELLISTER S, et al. Therapeutic silencing of KRAS using systemically delivered siRNAs[J]. Mol Cancer Ther, 2014, 13(12):2876-2885. [11] YUAN T L, FELLMANN C, LEE C S, et al. Development of siRNA payloads to target KRAS-mutant cancer[J]. Cancer Discov, 2014, 4(10):1182-1197. [12] MIRZAEI H, YAZDI F, SALEHI, et al.SiRNA and epigenetic aberrations in ovarian cancer[J]. Cancer Res Ther, 2016, 12(2):498-508. [13] AHMADZADA T, REID G, MCKENZIE D R. Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer[J]. Biophys Rev, 2018, 10(1):69-86. [14] VAISHNAW A K, GOLLOB J, GAMBA-VITALO C, et al. A status report on RNAi therapeutics[J]. Silence, 2010, 1(1):14. [15] BERNSTEIN E, CAUDY A A, HANNNOND S M, et al. Role for a bidentate ribonuclease in the initiation step of RNA interference[J].Nature,2001,409:363-366. [16] LENG Q X, WOODLE M C, LU P Y, et al. Advances in systemic siRNA delivery[J]. Drugs Future, 2009, 34(9):721. [17] JENNY G PARVANI, MARK W JACKSON. Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles[J]. Endocrine-Related Cancer, 2017,24(4):R81-R97. [18] CULLIS P R, HOPE M J. Lipid nanoparticle systems for enabling gene therapies[J]. Mole Ther,2017,25(7):1467-1475. [19] SUCKFUELL M, CANIS M, STRIETH S, et al. Intratympanic treatment of acute acoustic trauma with a cell-permeable JNK ligand:a prospective randomized phase Ⅰ/Ⅱ study[J].Acta Otolaryngol, 2007,127(9):938-942. [20] SUCKFUELL M, LISOWSKA G, DOMKA W, et al. Efficacy and safety of AM-111 in the treatment of acute sensorineural hearing loss:a double-blind, randomized, placebo-controlled phase Ⅱ study[J].Otol Neurotol, 2014, 35(8):1317-1326. [21] BEYDOUN T, DELOCHE C, PERINO J, et al. Subconjunctival injection of XG-102, a JNK inhibitor peptide, in patients with intraocular inflammation:a safety and tolerability study[J].J Ocul Pharmacol Ther,2015,31(2):93-99. |